Testosterone extended-release - GlaxoSmithKline

Drug Profile

Testosterone extended-release - GlaxoSmithKline

Alternative Names: T-8 oral testosterone - GlaxoSmithKline; Testosterone-extended-release

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; University of Washington
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Hypogonadism

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypogonadism(In volunteers) in USA (PO, Controlled release)
  • 23 Jan 2015 Biomarkers information updated
  • 01 Jun 2012 GlaxoSmithKline completes a phase I trial in volunteers in USA (NCT01167829)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top